Alpfa Medical, Inc.
StreetZero Signal 73
About Alpfa Medical, Inc.
Alpfa Medical develops minimally invasive pulsed field ablation (PFA) systems to treat soft tissue conditions, with a major focus on benign prostatic hyperplasia (BPH). The company invents and builds breakthrough medical devices as engineers and custodians of pulsed field ablation technology already used in cardiology and now targeting urology. ALPFA GRAIL is for investigational use only and is being studied in clinical trials.
LATEST FUNDINGPrivate Placement
$80.3M
Announced 2026-09-28
TOTAL RAISED$80,268,077
IN THE NEWS
- 🔗 Alpha Medical Announces New Funding of $24M to Further its Leadership in Women's Health
- 🔗 Alpha Medical closes $24M Series B round to expand women's telehealth -- without the video calls | TechCrunch
- 🔗 ALPFA Inc - Association of Latino Professionals For America Company Overview, Contact Details & Competitors | LeadIQ
- 🔗 Alpfa Medical
- 🔗 About ALPFA
EMPLOYEES—
FOUNDED—
HQPALO ALTO, CA
Industry
Other Health Care
Tags
Medical DevicesPFAHealthcare
Investors
Not disclosed in the source filing. Form D filings do not list investors — StreetZero surfaces them from news where available.
Key highlights
- Raised $80M via private placement in Palo Alto, CA.
- Develops pulsed field ablation systems for soft tissue and BPH treatment.
- Early-stage equity financing closed December 2024.
- Technology builds on PFA use in cardiology for urology applications.
Ask StreetZero about Alpfa Medical, Inc.
Put our AI to work on this deal.
Similar companies
Other Other Health Care deals, ranked by Signal.
Source document & SEC filing
The source SEC filing and the cached document are available to members only. Sign in to view and download them.
Sign in to view the filing Create free account